Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in severe chronic kidney disease
2021-005446-15Phase 3Active
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and heart failure (HF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Time to composite endpoint. Started Mar 2022; status: active.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on 2021-005446-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005446-15.